Saverio La Francesca Net Worth

The estimated Net Worth of Saverio La Francesca is at least $1.18 Million dollars as of 24 August 2017. Saverio Francesca owns over 100,000 units of Biostage stock worth over $1,184,812 and over the last 8 years Saverio sold BSTG stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Saverio Francesca BSTG stock SEC Form 4 insiders trading

Saverio has made over 2 trades of the Biostage stock since 2017, according to the Form 4 filled with the SEC. Most recently Saverio bought 100,000 units of BSTG stock worth $37,000 on 24 August 2017.

The largest trade Saverio's ever made was buying 150,000 units of Biostage stock on 23 August 2017 worth over $48,000. On average, Saverio trades about 83,333 units every 0 days since 2017. As of 24 August 2017 Saverio still owns at least 293,998 units of Biostage stock.

You can see the complete history of Saverio Francesca stock trades at the bottom of the page.

What's Saverio Francesca's mailing address?

Saverio's mailing address filed with the SEC is C/O BIOSTAGE, INC., 84 OCTOBER HILL ROAD, SUITE 11, HOLLISTON, MA, 01746.

Insiders trading at Biostage

Over the last 8 years, insiders at Biostage have traded over $962,849 worth of Biostage stock and bought 1,593,581 units worth $3,804,230 . The most active insiders traders include David Green, Capital Llc Dst und Ronald J Packard. On average, Biostage executives and independent directors trade stock every 79 days with the average trade being worth of $217,604. The most recent stock trade was executed by Capital Llc Dst on 6 April 2023, trading 62,500 units of BSTG stock currently worth $375,000.

What does Biostage do?

Biostage, Inc., a biotechnology company, engages in developing bioengineered organ implants based on its Cellframe technology. The company's Cellframe technology comprises a biocompatible scaffold that is seeded with the recipient's own stem cells. It is developing its Cellframe technology to treat life-threatening conditions of the esophagus, bronchus, or trachea. The company was formerly known as Harvard Apparatus Regenerative Technology, Inc. and changed its name to Biostage, Inc. in March 2016. Biostage, Inc. was founded in 2007 and is headquartered in Holliston, Massachusetts.

Complete history of Saverio Francesca stock trades at Biostage

Biostage executives and stock owners

Biostage executives and other stock owners filed with the SEC include:

• David Green,
  Director
• Dr. William L. Fodor Ph.D.,
  Chief Scientific Officer
• Yu Hong,
  Pres
• Thomas Robinson,
  Independent Director
• James Shmerling,
  Director
• Ting Li,
  Director
• Harout DerSimonian,
  Chief Scientific Officer
• James Mastridge,
  Interim Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
• Hong Yu,
  President
• Jason Jing Chen,
  Chairman of the Board
• Dr. Shunfu Hu Ph.D.,
  VP of Bus. Devel. & Operations
• Peter A. Pellegrino Jr.,
  Interim VP of Fin.
• David Green,
  CEO & Chairman
• Blaine H. Mc Kee,
  Director
• Saverio La Francesca,
  See Remarks
• John J Canepa,
  Director
• Thomas Mc Naughton,
  Chief Financial Officer
• John F Kennedy,
  Director
• James Joseph Mc Gorry,
  Chief Executive Officer
• William Fodor,
  Chief Scientific Officer
• Herman Sanchez,
  Director
• Xiaoyu Du,
  10% owner
• Matthew D Dallas,
  Director
• Wei Zhang,
  Director
• Jeffrey E Young,
  Director
• Peter M Chakoutis,
  Vice President of Finance
• Ronald J Packard,
  Director
• Capital Llc Dst,
  10% owner
• Jing Chen,
  
• Junli He,
  CEO
• Joseph Luis Jr Damasio,
  Chief Financial Officer